<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783925</url>
  </required_header>
  <id_info>
    <org_study_id>16469</org_study_id>
    <secondary_id>EY1310KR</secondary_id>
    <nct_id>NCT01783925</nct_id>
  </id_info>
  <brief_title>Eylea Post Marketing Surveillance(PMS)</brief_title>
  <official_title>Eylea Post Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this PMS is to gain information about safety and efficacy in real practice
      as a regulatory commitment required by MFDS
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2014</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart. [BCVA: Best Corrected Visual Acuity]</measure>
    <time_frame>4 months or 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness by OCT with or without.[OCT: Optical Coherence Tomography]</measure>
    <time_frame>4 months or 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Findings of FAG and/or ICAG. [FAG: Fluorescein Angiography].ICAG: Indocyanine Green Angiography]</measure>
    <time_frame>4 months or 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP(if performed, before/after injection).[IOP: Intra Ocular Pressure]</measure>
    <time_frame>4 months or 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of fundus lesion by fundoscopy</measure>
    <time_frame>4 months or 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3206</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with wet age-related macular degeneration(wAMD), RVO, DME, and mCNV who
        are decided to receive EYLEA (VEGF Trap Eye) treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients determined to start EYLEA treatment

          -  Patients who agree and sign informed consent

          -  Patients who receive EYLEA treatment for the first time

          -  Patients who meet one of the following

               -  Patients diagnosed by physician as having neovascular (wet) age-related macular
                  degeneration wAMD

               -  Patients diagnosed by physician as having visual impairment due to macular edema
                  secondary to retinal vein occlusion (branch RVO or central RVO)

               -  Patients diagnosed as having visual impairment due to diabetic macular edema
                  (DME)

               -  Patients diagnosed as having visual impairment due to myopic choroidal
                  neovascularization (mCNV)

        Exclusion Criteria:

          -  Patients who have received anti-VEGF therapy within 90 days

          -  Patients who are contraindicated based on the approved product label

               -  Ocular or periocular infection

               -  Active severe intraocular inflammation

               -  Known hypersensitivity to any ingredient of this drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

